A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)

Inclusion criteria:

1. Male or female participants ≥12 years old on the day of signing informedconsent/assent (Visit 1)

2. Weight of ≥40 kg at the screening visit (Visit 1)

3. Body mass index (BMI) of ≤40 kg/m² at the screening visit (Visit 1)

4. Participants with a diagnosis prior to the screening visit (Visit 1) of either:

• Biopsy-confirmed primary focal segmental glomerulosclerosis (pFSGS) (based onInvestigator's judgement) OR

• Genetic focal segmental glomerulosclerosis (FSGS) resulting from again-of-function mutation in the transient receptor potential cation subfamilyC member 6 (TRPC6) gene (based on historical genetic test)

5. Urine protein-creatinine ratio (UPCR) ≥1500 mg/g based on the mean of the spot urinesample and first morning void urine sample (both assessed by central laboratory) atthe screening visit (Visit 1)

6. Estimated glomerular filtration rate (eGFR)

• For adult participants (≥18 years): ≥25 mL/min/1.73 m² (chronic kidney diseaseepidemiology collaboration (CKD-EPI) formula based on combined serum creatinineplus cystatin C) at the screening visit (Visit 1)

• For adolescent participants (12 to <18 years); ≥25 mL/min/1.73 m² based onchronic kidney disease under 25 years (CKiD U25) formula using height and serumcystatin C at the screening visit (Visit 1) Further inclusion criteria apply.

Exclusion criteria:

1. Known monogenic or syndromic causes of FSGS (with the exception of TRPC6gain-of-function gene mutations)

2. Clinical or histologic evidence of secondary maladaptive or toxic forms of FSGS (based on Investigator's judgement)

3. FSGS of undetermined cause (FSGS-UC) with a diagnosis prior to the screening visit (Visit 1) (based on Investigator's judgement)

4. A history of organ transplantation or planned organ transplantation during thecourse of the trial

5. Use of intravenous immunosuppressive agents (e.g. cyclophosphamide, rituximab,obinutuzumab) in the last 6 months prior to screening (Visit 1) Further exclusioncriteria apply.